SynthesisWorld journal of urology2026
ctDNA-guided or ctDNA-stratified adjuvant immunotherapy compared with observation or placebo after radical surgery for muscle-invasive urothelial carcinoma: a GRADE-assessed systematic review and meta-analysis.
Synthesis in World journal of urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAdjuvant immunotherapy after radical surgery for muscle-invasive urothelial carcinoma has produced heterogeneous trial-level results, partly because clinicopathological risk factors do not completely identify patients with molecular residual disease (MRD). Circulating tumor DNA may refine postoperative treatment selection by distinguishing patients who are most likely to benefit from immune checkpoint inhibition from those who may experience unnecessary toxicity.
methodsThis systematic review and meta-analysis was conducted according to the for Systematic Reviews and Preferred Reporting Items Meta-Analyses 2020 guidelines. PubMed/MEDLINE, Embase, and Scopus were searched from their inception until May 2026. Prospective comparative studies evaluating ctDNA-guided or ctDNA-stratified adjuvant immunotherapy versus observation or placebo after radical surgery for muscle-invasive urothelial carcinoma were included. Hazard ratios were pooled for time-to-event outcomes using generic inverse variance models, and risk ratios were pooled for dichotomous safety outcomes using Mantel-Haenszel random-effects models. The risk of bias was assessed using ROB2, and the certainty of evidence was evaluated using GRADE.
resultsFive reports representing three independent randomized trial datasets were included. The ctDNA-defined efficacy population included 310 patients receiving adjuvant immunotherapy and 208 receiving observation or placebo, whereas the pooled safety analysis included 632 and 529 patients, respectively. ctDNA-guided or ctDNA-stratified adjuvant immunotherapy significantly improved disease-free survival (HR 0.46, 95% CI 0.32-0.66; P < 0.0001; I²=38%) and overall survival (HR 0.56, 95% CI 0.44-0.72; P < 0.00001; I²=0%). Any-grade adverse events were not significantly increased (RR 1.05, 95% CI 0.98-1.12), nor were grade ≥ 3/3-4 adverse events (RR 1.44, 95% CI 0.98-2.11) or serious adverse events (RR 1.25, 95% CI 0.87-1.80).
conclusionsctDNA-guided or ctDNA-stratified adjuvant immunotherapy after radical surgery was associated with improved disease-free and overall survival without a statistically significant pooled increase in major toxicities. ctDNA is a promising tool for residual molecular disease that may inform postoperative immunotherapy selection; however, current evidence remains insufficient to establish ctDNA-guided selection as a definitive standard of care. Implementation should remain linked to validated assay platforms, patient fitness assessment, and individualized shared decision-making. CLINICAL
trial registrationNot applicable. This study was not a clinical trial.
Indexed as
Identifiers
42661024What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.